This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohn, J. N Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N Social Bookmarking                         What's this?

Rationale for angiotensin II receptor blocker therapy in chronic heart failure

University of Minnesota Medical School, Minneapolis, USA

Inhibiting the synthesis of angiotensin II (Ang II) by angiotensin-converting enzyme (ACE) inhibitor treatment has long been established as the recommended therapy for heart failure (HF). As ACE inhibitors are only partially effective in blocking the formation of Ang II, additional treatment with selective Ang II receptor blockers (ARBs) promise additional benefits in patients with HF. This hypothesis is currently being evaluated in Val-HeFT, a large-scale, randomised, double-blind, placebo-controlled study on the effects of adding the highly selective ARB valsartan to usual therapy (diuretics, digoxin, beta-blockers, ACE inhibitors) for HF treatment.

Key Words: congestive heart failure • angiotensin II • combination treatment • angiotensin II receptor blockade • mortality study

References

• Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.[Abstract/Free Full Text]
• Cohn JN Vasodilator therapy for heart failure. The influence of impedance on left ventricular performance. Circulation 1973;48:5-8.[Free Full Text]
• Aceto JF, Baker KM [SAR'] Angiotensin II receptor-mediated stimulation of protein synthesis in chick heart cells. Am J Physiol 1990;258:H806-13.[Web of Science][Medline] [Order article via Infotrieve]
• Baruch L., Anand I., Cohen IS et al. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group Circulation 1999;9: 2658-64.
• Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990-2.[Abstract/Free Full Text]
• McKelvie RS,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056-64.[Abstract/Free Full Text]
• Cohn JN Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial. Cardiology 1999;91(Suppl 1):19-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Presented at the meeting of the American Heart Association in November 2000.

Journal of Renin-Angiotensin-Aldosterone System, Vol. 1, No. 2 suppl, S38-S40 (2000)
DOI: 10.3317/jraas.2000.055


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cohn, J. N Search for Related Content PubMed PubMed Citation Articles by Cohn, J. N Social Bookmarking                         What's this?